Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 27;12:820191. doi: 10.3389/fphar.2021.820191

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Tregnago, Benetton, Da Ros, Borella, Longo, Polato, Francescato, Biffi and Pigazzi.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Combination of venetoclax and quinacrine. (A) Cell viability of SHI-1 and NOMO-1 [both KMT2A-rearranged acute myeloid leukemia (AML)] and HL-60 (non-KMT2A-rearranged AML) after treatment with quinacrine combined with venetoclax at 48 h after treatment. The synergy scores were represented by pseudocoloring 2-dimensional contour plots over the dose matrix (red indicates synergy and green indicates antagonism) and calculated using the ZIP model (synergy when >10, n = 2). Stars indicate the concentrations selected for subsequent experiments. (B) Cell viability of SHI-1 and NOMO-1 (KMT2A-arranged) or HL-60 (non-KMT2A-rearranged) after treatment with venetoclax, quinacrine, or the combination at 48 h after treatment (CI, combination index; synergy when CI <1. ANOVA test was performed by applying Bonferroni correction for multiple statistical hypotheses testing. ***p < 0.001, ****p < 0.0001; n = 2).